Back to top
more

DaVita (DVA)

(Delayed Data from NYSE)

$129.50 USD

129.50
949,567

+1.81 (1.42%)

Updated Aug 8, 2025 04:00 PM ET

After-Market: $129.00 -0.50 (-0.39%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 21% (51 out of 244)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Founded in 1994 and headquartered in Denver, CO, DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services.

Zacks Equity Research

AngioDynamics (ANGO) Q2 Earnings Top Estimates, Revenues Miss

by Zacks Equity Research

AngioDynamics (ANGO) registers strong revenue growth in the Med Tech business in second-quarter fiscal 2024.

Zacks Equity Research

Boston Scientific (BSX) Rides on Global Growth Amid Macro Woes

by Zacks Equity Research

Within APAC, Boston Scientific (BSX) is registering strong growth in Japan and China.

Zacks Equity Research

Avanos (AVNS) Preliminary Q4 Revenues Dampened by Lower Sales

by Zacks Equity Research

Avanos' (AVNS) revenue growth in the fourth quarter is likely to have been dampened by lower HA pain relief injection product sales.

Zacks Equity Research

Veradigm's (MDRX) Acquires Koha Health to Solidify Market Presence

by Zacks Equity Research

Veradigm's (MDRX) acquisition of Koha Health will likely enhance its ability to deliver efficient revenue cycle services by incorporating Musculoskeletal Medicine specialty subject matter expertise.

Zacks Equity Research

Bruker's (BRKR) New Deal Widens Biopharma PAT Product Portfolio

by Zacks Equity Research

Bruker (BRKR) announces the acquisition of Tornado Spectral Systems Inc., a global provider of chemical analysis & measurement systems for Raman spectroscopy.

Zacks Equity Research

Reasons to Retain The Cooper Companies (COO) in Your Portfolio Now

by Zacks Equity Research

The Cooper Companies (COO) benefits from strength in its business segments. Its acquisitions are likely to drive the top line. A rise in selling, general and administrative expenses is concerning.

Zacks Equity Research

Best Growth Stocks to Buy for January 5th

by Zacks Equity Research

BROS, DVA and EVBG made it to the Zacks Rank #1 (Strong Buy) growth stocks list on January 5, 2024.

Zacks Equity Research

Walgreens Boots (WBA) Q1 Earnings Top Estimates, Margins Down

by Zacks Equity Research

Walgreens Boots' (WBA) comparable pharmacy sales in the fiscal first quarter benefited from higher branded drug inflation and strong execution in pharmacy services.

Zacks Equity Research

Here's Why You Should Retain Myriad Genetics (MYGN) Stock Now

by Zacks Equity Research

Investors are optimistic about Myriad Genetics (MYGN) on robust testing volumes and strong solvency position.

Zacks Equity Research

McKesson (MCK) Hits 52-Week High: What's Driving the Stock?

by Zacks Equity Research

Investors are optimistic about McKesson's (MCK) strength in its Biologics business.

Zacks Equity Research

Enovis (ENOV) to Strengthen Portfolio Via Its Latest Buyout

by Zacks Equity Research

Enovis' (ENOV) latest buyout is expected to expand its international scale with a complementary global customer base and product mix and improve efficiency with innovative manufacturing facilities.

Zacks Equity Research

Bruker (BRKR) Expands Materials Science Research via New Deal

by Zacks Equity Research

Bruker (BRKR) announces the acquisition of the electron microscopy company Nion.

Zacks Equity Research

Here's Why Investors Should Retain STERIS (STE) Stock for Now

by Zacks Equity Research

Investors continue to remain optimistic about STERIS (STE) due to the prospects of the healthcare business.

Zacks Equity Research

Reasons to Retain Stryker (SYK) Stock in Your Portfolio Now

by Zacks Equity Research

Stryker (SYK) continues to benefit from strength in the robotic arm-assisted surgery platform, Mako, and its broad product portfolio.

Zacks Equity Research

Reasons to Hold West Pharmaceutical (WST) in Your Portfolio Now

by Zacks Equity Research

West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex concerns persist.

Zacks Equity Research

Haemonetics (HAE) Up 11% in a Year: Will the Rally Continue?

by Zacks Equity Research

Investors are optimistic about Haemonetics (HAE) owing to its strategic focus on establishing leading positions in high-growth markets and raised guidance.

Zacks Equity Research

Reasons to Retain Quest Diagnostics (DGX) Stock for Now

by Zacks Equity Research

Investors are optimistic about Quest Diagnostics (DGX) on strength in base business and strategic collaborations.

Zacks Equity Research

Cencora (COR) Hits 52-Week High: What's Aiding the Stock?

by Zacks Equity Research

Investors are optimistic about Cencora's (COR) strength in the U.S. Healthcare Solutions business.

Zacks Equity Research

Microbot Medical (MBOT) Announces Positive GLP Study Results

by Zacks Equity Research

Microbot Medical's (MBOT) latest favorable study results are likely to support its IDE submission to the FDA to commence its human clinical study.

Zacks Equity Research

Reasons to Retain ShockWave Medical (SWAV) in Your Portfolio Now

by Zacks Equity Research

ShockWave Medical (SWAV) continues to benefit from solid R&D endeavors and its commitment to clinical studies.

Zacks Equity Research

Best Growth Stocks to Buy for January 3rd

by Zacks Equity Research

BROS, DVA and EVBG made it to the Zacks Rank #1 (Strong Buy) growth stocks list on January 3, 2024.

Zacks Equity Research

Here's Why You Should Retain Humana (HUM) in Your Portfolio

by Zacks Equity Research

Humana (HUM) remains well-poised for growth, attributable to an aging U.S. population, contract wins, acquisitions and expanding cash reserves.

Zacks Equity Research

Here's Why You Should Retain Medtronic (MDT) Stock for Now

by Zacks Equity Research

Investors are optimistic about Medtronic's (MDT) expansion in global markets and stable solvency position.

Zacks Equity Research

3 Reasons to Hold Inogen (INGN) Stock in Your Portfolio

by Zacks Equity Research

Inogen's (INGN) potential in the POC space and a strong product portfolio raise optimism about the stock.

Ethan Feller headshot

Bull of the Day: DaVita (DVA)

by Ethan Feller

DaVita has a strong long-term stock performance and multiple bullish catalysts